US EditionContinuous Manufacturing Helps mAb Firms Innovate and Cut Costs
Continuous manufacturing makes monoclonal antibody production faster, cheaper, and greener, say researchers, who predict that industry adoption of the approach will accelerate in response to competitive pressure. Most therapeutic antibodies are made as batches, using discrete processes that run for a defined period. This, in large part, reflects the success of early drugs like Enbrel, Humira, and Avastin, which established fed-batch processes as…
1 Articles
1 Articles
All
Left
Center
Right
Continuous Manufacturing Helps mAb Firms Innovate and Cut Costs
Continuous manufacturing makes monoclonal antibody production faster, cheaper, and greener, say researchers, who predict that industry adoption of the approach will accelerate in response to competitive pressure. Most therapeutic antibodies are made as batches, using discrete processes that run for a defined period. This, in large part, reflects the success of early drugs like Enbrel, Humira, and Avastin, which established fed-batch processes as…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
